Eli Lilly’s patent win in France a ‘game changer’

Generic maker ordered to pay €28m in damages for infringing an Eli Lilly patent covering its Alimta product; signals a ‘sea change’ in the way French courts approach pharma infringement cases

Ben Wodecki

Pharma giant Eli Lilly has successfully stopped Fresenius Kabi from commercialising its infringing generic version of its oncology drug, Alimta.